Satelia
Satelia is a French digital health company operating Satelia® Cardio, a CE-marked Class IIa remote patient monitoring platform for chronic heart failure patients. It combines a symptom-based algorithm with a human nurse support team (Télesphore) to serve 500+ French healthcare providers and 11,000+ patients.
- Company typePrivate
- Founded2017
- HeadquartersBordeaux, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Satelia does
Satelia is a French digital health company that operates a remote patient monitoring platform purpose-built for chronic heart failure. Its core product, Satelia® Cardio, is a CE-marked Class IIa medical device software that uses structured symptom-based questionnaires — rather than connected devices or wearable sensors — to monitor patients weekly, with results processed by a proprietary algorithm that has demonstrated a 99.43% negative predictive value in identifying low-risk patients in the multicenter TELESAT-HF study. Approximately 77% of monitored patients self-report via a web application, while the remaining 23% are reached by telephone through Télesphore, an in-house paramedical and medical team of nurses, physicians, and medical secretaries that addresses digital exclusion among elderly and non-technophile patients (median patient age 73, over 50% aged 75+).
The company generates revenue via monthly operator fees (forfait opérateur) billed to French healthcare institutions under the national telemonitoring reimbursement framework (Sécurité Sociale), at the TVB rate of €28/patient/month for heart failure. The solution is sold exclusively through institutional channels — hospitals, cardiology practices, and university hospitals — via direct enterprise engagement and through the UniHA and Resah public procurement catalogs. Satelia is trusted by 500+ care providers including approximately one-third of French university hospitals and monitors 11,000+ patients nationwide. Clinical validation includes a 36% reduction in all-cause mortality demonstrated in the TELESAT-HF real-world study and an 87% patient satisfaction rate across 825 monitored patients.
Founded in 2017 by anesthesiologist-intensivist Nicolas Pagès and incorporated as NP Medical (société par actions simplifiée), Satelia is headquartered in Bordeaux. The company raised €10 million from Impact Partners in October 2022 to fund algorithm development and European expansion, obtained CE Class IIa marking in 2025, and has signaled European geographic expansion as a core strategic priority, supported by a December 2024 migration of data hosting to OVHcloud for European data sovereignty.
Satelia firmographics
Firmographics- Name
- Satelia
- Legal name
- NP Medical
- Website
- https://satelia.eu
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Satelia is a French digital health company operating Satelia® Cardio, a CE-marked Class IIa remote patient monitoring platform for chronic heart failure patients. It combines a symptom-based algorithm with a human nurse support team (Télesphore) to serve 500+ French healthcare providers and 11,000+ patients.
- Ownership category
- akta.pro rank
Satelia industry classification
Industry- Product category
- Remote Patient Monitoring Software
- NAICS
- Home Health Care Services (62161), Telephone Call Centers (56142)
- SIC
- Services-Health Services (8000), Services-Home Health Care Services (8082)
- akta.pro primary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
- akta.pro secondary industries
- Virtual Specialty Care Platforms (tele-stroke, tele-ICU, tele-derm, tele-cardiology) (HLALABAD), 24/7 Nurse Line, Symptom Checker & Triage (Payer-Sponsored) (HLALACAB), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)
Keywords
Where Satelia is headquartered
LocationHeadquarters
- HQ city
- Bordeaux
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Satelia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Healthcare Reimbursement (French National Health Insurance): Satelia Cardio is reimbursed through the French national health insurance system (Sécurité Sociale). It is covered at 100% for patients with exemption from copayment (ticket modérateur) and at 60% under standard coverage. Specific rates apply for certain special regimes. Revenue is generated through operator fees billed monthly to healthcare facilities under the national telemonitoring framework.
- Healthcare Cost Savings (Social Entrepreneurship Model): Satelia is financed by the healthcare cost savings it generates for payers (French social security and mutual insurance funds), specifically by avoiding hospitalizations, improving quality of life, and delaying dependence. This outcome-based model aligns company revenue with measurable clinical and economic benefits.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Reimbursed telemonitoring for heart failure patients via French national health insurance |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Satelia product offering
Product offeringCore offering
Satelia develops and sells Satelia® Cardio, a Class IIa CE-marked medical device software for remote telemonitoring of chronic heart failure patients. The solution relies on symptom-based questionnaires submitted via web or telephone — no connected devices or app installation required — combined with a proprietary algorithm that detects risk of cardiac decompensation with a 99.43% negative predictive value. The offering is delivered with the Télesphore human care team (nurses, physicians, medical secretaries) that provides direct phone-based support for patients with limited digital skills, and is fully reimbursed by the French national health insurance system.
Product overview
Satelia is a French digital health company offering a unified telemonitoring platform centered on Satelia® Cardio, a Class IIa CE-marked medical device for chronic heart failure patients. The solution comprises a web-based patient monitoring application, the Télesphore human support team (nurses, physicians, medical secretaries), and therapeutic patient education programs. Unlike connected device solutions, Satelia® Cardio relies on symptom questionnaires accessible to all patients regardless of digital literacy, with 77% of patients self-monitoring via internet and 23% assisted by Télesphore nurses. The platform integrates algorithmic risk detection to identify patients at risk of decompensation, supported by coordinated care pathway services.
Differentiator
Problem solved
Functional benefit
Brands
- Télesphore: A paramedical and medical team in direct contact with patients to fight against digital exclusion, providing personalized care journeys regardless of digital proficiency.
Products and services
- Satelia® Cardio A Class IIa CE-marked medical device software (CE 0476) for remote telemonitoring of chronic heart failure patients. Uses symptom-based questionnaires without requiring connected devices, allowing universal access regardless of digital literacy. Delivered to hospitals, clinics, and cardiology practices and prescribed by cardiologists.
- Télesphore A paramedical and medical support team (nurses, physicians, medical secretaries) providing direct contact with patients to enable telemonitoring for those with limited digital skills or facing digital exclusion. Delivered as part of the Satelia Cardio service to ensure universal patient coverage (23% of monitored patients are supported via phone by Télesphore nurses).
- Therapeutic Patient Support (ATP) Individual therapeutic education sessions provided by the Satelia medical team to support patients in managing their heart failure, including patient education, prevention guidance, and care pathway coordination throughout the patient's care journey.
Quantifiable outcome
- 36% reduction in all-cause mortality (TELESAT-HF study, 300+ centers, August 2018 – December 2022)
- +5 more outcomes
Companies that use Satelia
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
Satelia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Satelia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- OVHcloudcoreSatelia partnered with OVHcloud in December 2024 to migrate its data from a US hosting provider to OVHcloud, a French cloud provider. This move strengthens data sovereignty in the healthcare sector, ensuring data management meets the highest security and privacy standards. The migration supports compliance with French and European healthcare data regulations.
- ResahminorSatelia Cardio was integrated into the Resah catalog for healthcare procurement. Resah focuses on pooling and professionalizing purchasing and logistics across healthcare, medical-social, and social sectors, offering Satelia access to its member institutions for telemonitoring solutions.
- UniHAcoreSatelia Cardio was selected by UniHA, the first cooperative network of hospital purchasing in France, in the category of 'Digital Medical Device for Heart Failure Telemonitoring.' This allows NP Medical to submit bids for specific public procurement tenders launched within this category across UniHA's member public healthcare institutions.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Satelia competitors and assessment
Company assessmentDirect peers
- Implicity: French cardiac remote monitoring platform providing AI-powered analysis of implantable cardiac device data (pacemakers, ICDs). Direct peer to Satelia in the French heart failure telemonitoring space, with overlapping cardiologists and institutional buyers, but differentiated by device-data versus symptom-based approach.
- Biofourmis: Boston/Singapore-based RPM platform with strong heart failure focus and FDA-cleared algorithms. Competes in chronic disease RPM with wearable integration, addressing similar cardiology providers and payer-driven outcomes contracting models as Satelia.
- Health Recovery Solutions: US-based heart failure RPM platform providing tablet-based patient engagement and clinical monitoring. Direct competitor in chronic disease RPM targeting cardiology practices and hospital systems, with comparable patient-reported outcomes workflows.
- Huma (formerly Medopad): UK-based digital health platform offering RPM and remote patient management across multiple chronic conditions including heart failure. Comparable regulatory positioning (CE mark, NHS engagement) and provider-facing SaaS business model similar to Satelia's institutional offering.
- Vivify Health: US-based RPM platform focused on chronic disease management including heart failure, with mobile and tablet-based patient interfaces. Competes for similar hospital and cardiology provider contracts under value-based care arrangements analogous to Satelia's payer-sponsored model.
Regional players
- Better@Home (TMM Software): German heart failure telemonitoring provider serving cardiology practices across Germany with comparable symptom-based monitoring workflows. Regional peer addressing similar heart failure cohorts in a different European reimbursement environment, useful as a benchmark for Satelia's potential German expansion.
Emerging players
- Withings Health Solutions: French connected health device company (Withings) extending into B2B RPM with cellular-connected blood pressure monitors, scales, and sleep trackers for chronic disease management. Comparable French health-tech ecosystem presence with adjacent chronic disease RPM use cases but a device-centric rather than symptom-based approach.
- Cardiologs (now Philips): Paris-based AI cardiac diagnostics company using deep learning for ECG analysis, recently acquired by Philips. Adjacent French cardiac-AI peer operating in the same cardiology customer base with complementary but distinct functionality (diagnostic AI versus telemonitoring workflows).
Broad incumbents
- Doctolib: Dominant French health-tech platform for appointment booking, telemedicine, and increasingly patient management. While not a direct RPM competitor, Doctolib's scale and provider relationships in France create potential competitive threat if it extends into chronic disease telemonitoring, and overlaps in serving the same cardiologist customer base.
- Philips (Connected Care / Population Health): Global medtech incumbent with extensive telehealth, remote monitoring, and population health management offerings including chronic care suites. Broad incumbent providing overlapping capabilities as part of a wider portfolio, targeting hospital systems and cardiology departments similar to Satelia's institutional customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Satelia social profiles
Digital presenceSatelia compliance and trust
Trust signalCompliance3 records
Satelia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Satelia leadership team
Management profileNumber of profiles
Profiles2 records
Satelia funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Satelia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Satelia
What does Satelia do?
Satelia develops and sells Satelia® Cardio, a Class IIa CE-marked medical device software for remote telemonitoring of chronic heart failure patients. The solution relies on symptom-based questionnaires submitted via web or telephone — no connected devices or app installation required — combined with a proprietary algorithm that detects risk of cardiac decompensation with a 99.43% negative predictive value. The offering is delivered with the Télesphore human care team (nurses, physicians, medical secretaries) that provides direct phone-based support for patients with limited digital skills, and is fully reimbursed by the French national health insurance system.
Is Satelia a public or private company?
Satelia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Satelia founded?
Satelia was founded in 2017. It employs 51 to 100 people.
Where is Satelia based?
Satelia is headquartered in Bordeaux, France, in the Europe region.
How does Satelia make money?
Two revenue lines are on record. Healthcare Reimbursement (French National Health Insurance) is the primary driver. The others are healthcare Cost Savings (Social Entrepreneurship Model).
Who are Satelia's main competitors?
Direct peers on record are Implicity, Biofourmis, Health Recovery Solutions, Huma (formerly Medopad) and Vivify Health. Better@Home (TMM Software) is listed as a regional player. Emerging players are Withings Health Solutions and Cardiologs (now Philips). Broad incumbents are Doctolib and Philips (Connected Care / Population Health).
Does Satelia have an API?
No public API is recorded for Satelia.
What industry is Satelia in?
Satelia's product category is Remote Patient Monitoring Software. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLALABAD, Virtual Specialty Care Platforms (tele-stroke, tele-ICU, tele-derm, tele-cardiology). Its NAICS code is 62161 and its SIC code is 8000.